Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430065 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01430065 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 24 participants.
The verdict
NCT01430065, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study characterizes the pharmacokinetic effects of ASP015K on Tacrolimus in healthy volunteers.
Interventions
- DRUG Tacrolimus
- DRUG ASP015K
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01430065
The ClinicalTrials.gov registry entry for NCT01430065 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tacrolimus is the first listed.
NCT01430065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01430065 about?
NCT01430065 is a clinical study titled "Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers". This study characterizes the pharmacokinetic effects of ASP015K on Tacrolimus in healthy volunteers.
What is the current status of trial NCT01430065?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-06. Estimated completion is 2009-06.
What interventions are being tested in trial NCT01430065?
The interventions under investigation include: Tacrolimus (DRUG), ASP015K (DRUG).
Who is sponsoring clinical trial NCT01430065?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.